Joint venture pairs MindWave’s blockchain infrastructure and digital-asset-backed capital, in the form of staking, with Skalup’s insurance expertise to build reinsurance capacity in one of the world’s leading insurance
AUSTIN, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the
MATAWAN, N.J., Oct. 13, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), today announced that NILA, the
MATAWAN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), signed three agreements between
MATAWAN, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 2-year master
MATAWAN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- MindWave Innovations Inc. ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 12-month software development
MATAWAN, New Jersey, Sept. 24, 2026 (GLOBE NEWSWIRE) -- via IBN — MindWave Innovations Inc. ("MindWave"), a subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 12-month technology services
AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to
MATAWAN, New Jersey / GEORGE TOWN, Cayman Islands, Aug. 03, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("MindWave
MATAWAN, New Jersey, and GEORGE TOWN, Cayman Islands, July 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("MindWave
Trading Expected to Resume on NYSE American on Tuesday, May 5
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the "Inscobee Parties"),
LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apimeds Pharmaceuticals US, Inc.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) resulting from allegations that
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) resulting from allegations that
Rejects Allegations of MindWave Innovations, Inc. SEOUL, South Korea, March 25, 2026 (GLOBE NEWSWIRE) -- Inscobee Inc. ("Inscobee") and Apimeds, Inc., ("Apimeds Korea") today announced that on March 20, 2026,
